Bristol-Myers Squibb Company Ce (New York Stock Exchange:CELG-RI)
| Market Cap | 245.13M+283.4% |
| Revenue (ttm) | 49.19B+3.1% |
| Net Income | 9.28B+83.8% |
| EPS | 4.54+83.4% |
| Shares Out | 2.04B |
| PE Ratio | 0.03 |
| Forward PE | 0.02 |
| Dividend | n/a |
| Ex-Dividend Date | Mar 7, 2024 |
| Volume | 2,614 |
| Open | 0.12 |
| Previous Close | 0.10 |
| Day's Range | 0.12 - 0.13 |
| 52-Week Range | 0.02 - 0.27 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
Bristol-Myers Squibb Company Ce has a live Insider Score.
Scored on 0 qualifying trades from 0 insiders in the last 90 days.
About CELG-RI
Bristol Myers Squibb Company (BMS) operates as a biopharmaceutical enterprise, managing the entire lifecycle of its therapeutic products, from initial discovery and development to manufacturing, marketing, and distribution. Its diverse portfolio includes conventional small molecule drugs, advanced biologics (which are derived from biological processes), and specialized chimeric antigen receptor (CAR-T) cell therapies. The company was established in August 1933 and maintains its corporate headquarters in Princeton, New Jersey.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$CELG-RI stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in CELG-RI holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CELG-RI's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CELG-RI Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CELG-RI Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| Net product sales | $12.59B | 97.03% |
| Other revenues | $281.00M | 2.17% |
| Alliance revenues | $104.00M | 0.80% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CELG-RI patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CELG-RI from public contracts
Source: USAspending.gov
CELG-RI Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CELG-RI’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score